SOURCE: Optigenex Inc.

February 03, 2010 08:09 ET

Optigenex Inc. Announces Expansion of AC-11® Sales in Japan Through Its Exclusive Partner Itochu Corporation

Itochu's Sub-Licensee Koyo-sa Japan, a Premier Direct Sales and Marketing Company, Introduces Encapsulated AC-11® in Combination With GliSODin; Early Sales Results Are Positive as the New Product, Called AC-11® Melon, Is Introduced to Company's Extensive Network of 300,000 Plus Japanese Member Affiliates and Customers

NEW YORK, NY--(Marketwire - February 3, 2010) - Optigenex Inc. (PINKSHEETS: OPGX) announced today the introduction of AC-11®-melon, a new oral capsule formulated by its partner, Itochu Corporation, utilizing patented AC-11® in combination with GliSODin, a cantaloupe melon extract rich in the vegetable antioxidant enzyme (SOD). The protective benefits of GliSODin, in conjunction with the therapeutic benefits of AC-11® to help repair naturally the body's damaged DNA, offer a unique and highly effective combination for cellular wellness to health-conscious consumers*. Japan traditionally has been known for its highly educated and well-informed consumer population, especially in the area of healthy aging. The enthusiastic response to Koyo-sa Japan's rollout of AC-11®-melon validates this reputation and constitutes another step forward in the evolution of AC-11® as one of the most popular health and wellness technologies in Japan.

Itochu acts in partnership with Optigenex under a Long-Term Exclusive Supply and Trademark Licensing Agreement to market AC-11® bulk material and consumer products containing AC-11® under sublicenses in Japan and several other Asian countries. To date, the company has introduced AC-11® successfully to over 110 companies in the cosmetic and dietary supplement market, with 130 plus products containing AC-11® currently being marketed and sold in Japan. AC-11® is the patented, all-natural rain forest botanical extract produced by Optigenex that helps the body's natural ability to repair damage to DNA due to multiple causes, including harmful effects of UV radiation (over-exposure to the sun), stress, environmental pollution and other stressors. In its standard bulk powder form, AC-11® supplement may be consumed orally or combined with liposomes and other delivery mechanisms for topical application to the skin.

Daniel Zwiren, president and CEO of Optigenex Inc., said, "We are excited about the Koyo-sa's new product and anticipate further expanded growth in sales this year of AC-11® to Japan, not only for AC-11®-melon but for other AC-11® nutraceutical products as our message for cellular wellness and healthy aging continues to take hold with our customers."

Yusuke Itou of Itochu Corporation added, "Koyo-sa is the largest network marketing company in Japan. We are extremely pleased that they have decided to market AC-11®-melon and that they recognize the importance of combining synergistic ingredients for new and robust products." Mr. Itou continued, "We fully expect to augment sales and volume of bulk purchases significantly in 2010 and beyond as our customers integrate AC-11® into existing products and formulate new products utilizing AC-11® as the main ingredient."

About ITOCHU Corporation:

Itochu Corporation is one of Japan's leading trading companies and is engaged in a wide variety of businesses, including food products, personal care products, textiles, technology multimedia, metals, energy, chemicals, forest products, retail and financial services. Itochu has approximately 45,690 employees, maintains over 130 offices and owns over 651 subsidiaries and affiliates around the world. Itochu's sales last year reached 11.58 trillion yen (U.S. $95 billion).

About Optigenex Inc.:

Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring as its core product AC-11® (formerly known as C-MED-100®) a patented, bioactive and water soluble rain forest compound derived from the medicinal herb Uncaria tomentosa. For more information about Optigenex please visit our website:

*The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to diagnose, treat, cure or prevent any disease.

Contact Information